Treatment of patients with advanced ovarian cancer who have had failure of systemic chemotherapy is rarely effective. Preliminary pharmacokinetic studies established the feasibility of delivering relatively high concentrations of cisplatin intraperitoneally via a semipermanent catheter, 9 patients with advanced ovarian cancer, 3patients of whom had failure os systemic chemotherapy, were treated with high-dose intraperitoneal cisplatin(100 mg/m2). Of the 9 patients evaluable for response, 5(56%)disappearance of malignant ascitew, 4(44%) showed a clinical partial response. Side effect consisted of nausea and vomiting(9 cases), hepatotoxicity(1 case), nephrotoxicity (1 case) and bone marrow depression(1 case). One Patient had treatment cased after one coruse of intraperitoneal chemotherapy due to hepatotoxicity nephrotocicity and bone marrow depression. It is felt that prospective studies to compare the efficacy of intraperitoneal chemotherapy with other forms of " salvage" therapy, as well as its use as initial chemotherapy for advanced ovarian cancer, need to be done.